Embryonic neural cell therapy-Parkinson's Disease - CellFactorsAlternative Names: Parkinson's disease cell therapy - CellFactors
Latest Information Update: 09 Aug 2007
At a glance
- Originator CellFactors
- Mechanism of Action Dopaminergic cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 09 Aug 2007 Discontinued - Preclinical for Parkinson's disease in United Kingdom (Intracerebal)
- 19 Jul 2001 Preclinical development for Parkinson's disease in United Kingdom (Intracerebal)